专利检索_ ..链霉菌属专利检索_ ..链霉菌属专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
301	ML-236B Derivatives and their preparation	US351974	1982-02-24	US4410629A	1983-10-18	Akira Terahara; Minoru Tanaka
Compounds of formula (I): ##STR1## (wherein R represents a group of formula ##STR2## and the corresponding ring-closed lactones, salts (especially alkali metal salts) and esters (especially C.sub.1 -C.sub.5 alkyl esters) thereof may be prepared by subjecting ML-236B, or ML-236B carboxylic acid or a salt or ester thereof to enzymatic hydroxylation, which may be effected by means of microorganisms of the genera Mucor, Rhizopus, Zygorynchus, Circinella, Actinomucor, Gongornella, Phycomyces, Martierella, Pycnoporus, Rhizoctonia, Absidia, Cunninghamella, Syncephalastrum and Streptomyces, or cell-free, enzyme-containing extracts from said microorganisms. The compounds are capable of inhibiting biosynthesis of cholesterol and are thus useful in the treatment of hypercholesteraemia.
302	Antibiotic SF-2103A substance and process for production thereof	US293063	1981-08-17	US4404218A	1983-09-13	Tatsuo Ito; Takashi Shomura; Michio Kojima; Norio Ezaki; Masaji Sezaki; Tomizo Niwa
An antibiotic SF-2103A substance or a salt thereof, and a process for the production thereof are described, and the process comprises cultivating an antibiotic SF-2103A substance-producing strain in a nutrient medium and recovering the desired substance from the culture broth.
303	Anthracycline antibiotics	US307832	1981-10-02	US4401812A	1983-08-30	Akiko Fujiwara; Tatsuo Hoshino; Masaaki Tazoe
The present invention is concerned with novel anthracyclines which are compounds of the general formula, ##STR1## wherein R.sub.1 is a methyl or acetonyl group and R.sub.2 is selected from the group consisting of ##STR2## Also presented is a method of making the above compounds. The compounds possess antibacterial and antitumor activities.
304	Process for the preparation of the antibiotic oxanosine	US323650	1981-11-20	US4394446A	1983-07-19	Hamao Umezawa; Nobuyoshi Shimada; Hiroshi Naganawa; Tomohisa Takita; Masa Hamada; Tomio Takeuchi
The novel antibiotic, oxanosine, having the structure ##STR1## inhibits the growth of Gram-negative bacteria and has antiviral and carcinostatic activity. It is produced by cultivation of an oxanosine-producing microorganism of the genus Streptomyces, preferably Streptomyces capreolus MG265-CF3, ATCC No. 31963.
305	Process for preparing thienamycin	US244857	1981-03-18	US4371617A	1983-02-01	Kentaro Tanaka; Naoki Tsuji; Eiji Kondo; Yoshimi Kawamura
A new process for preparing thienamycin, a known antibiotic useful as a medicament and veterinary drug, characterized by cultivating Streptomyces penemifaciens sp. nov. in a suitable medium and recovering thienamycin from the fermentation broth.
306	11-Deoxy-carminomycin compounds	US94671	1979-11-15	US4370474A	1983-01-25	Giuseppe Cassinelli; Arpad Grein; Sergio Merli; Giovanni Rivola
Anthracycline glycosides W, X, Y and Z which are prepared by the fermentation of mutant F.I. 416 of Streptomyces peucetius var. caesius. The new compounds are useful against both gram positive and gram negative bacteria and as antitumor agents.
307	Process for treating malaria	US255541	1981-04-20	US4368193A	1983-01-11	Alexander D. Argoudelis; David W. Stroman
A process for treating a protozoan disease, for example, malaria, by the systemic administration to a subject hosting a malarial parasite of the 3-(5'-ribonucleotide) of a novel analog of the well-known antibiotics lincomycin and clindamycin. The analogs are prepared by condensing a cyclic acid with a sugar amine. The 3-ribonucleotides of these analogs can be prepared by microbiological transformation procedures.
308	Maytansinoids	US188238	1980-09-17	US4364866A	1982-12-21	Mitsuko Asai; Kazuo Nakahama; Motowo Izawa
Antibiotic C-15003 PHO of the formula: ##STR1## wherein R.sub.1 is H, hydroxyl, alkanoyloxy, alkenylcarbonyloxy or arylcarbonyloxy; R.sub.2 is H, hydroxyl or alkanoyloxy; R.sub.3 is H or alkanoyloxy is produced by introducing a hydroxyl group into 15-position of a maytansinoid compound, and, if desired, thus obtained compound is subjected to deacylation or acylation.Antibiotic C-15003 PHO is useful as antiprotozoal or antitumor agent.
309	Polycyclic ether antibiotic	US285264	1981-07-20	US4361649A	1982-11-30	Walter D. Celmer; Walter P. Cullen; Riichiro Shibakawa; Junsuke Tone
A new acidic polycyclic ether antibiotic has the formula: ##STR1## and can be prepared by the submerged aerobic propagation in aqueous nutrient media of Streptomyces halstedii ATCC 31812. The antibiotic and its cationic salts are active against a variety of microorganisms and are effective in controlling coccidiosis, enteritis, swine dysentery and theileriosis as well as being effective in promotion of growth in poultry and ruminants.
310	Peptide, process for preparation thereof and use thereof	US22907281	1981-01-28	US4349466A	1982-09-14	KITAURA YOSHIHIKO; NAKAGUCHI OSAMU; HEMMI KEIJI; ARATANI MATSUHIKO; TAKENO HIDEKAZU; OKADA SATOSHI; TANAKA HIROKAZU; HASHIMOTO MASASHI; KURODA YOSHIO; IGUCHI EIKO; KOHSAKA MASANOBU; AOKI HATSUO; IMANAKA HIROSHI
The invention relates to novel peptides and their pharmaceutically acceptable salts particularly useful for pharmaceutical purposes such as in the therapeutic treatment of infectious diseases caused by pathogenic microorganisms. The compounds have the structure: <IMAGE> wherein R1 is hydrogen or acyl; R2 and Rq are each hydrogen, carboxy, protected carboxy, or a group of the formula <IMAGE> wherein Ra2 is mono- or di-carboxy or protected carboxy lower alkyl or ar(carboxy or protected carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy, Rb2 is hydrogen or lower alkyl; Rp is hydrogen, carboxy, protected carboxy, with proviso that when one of R2 and Rq is hydrogen, then the other is carboxy, or protected carboxy, or a group of the formula <IMAGE> wherein Ra2 and Rb2 are each as defined above; Rr is hydrogen or aminoprotective group, m is an integer 1 to 3, and their pharmaceutically acceptable salts.
311	Process for preparing narasin	US261068	1981-05-06	US4342829A	1982-08-03	Ralph E. Kastner; Robert L. Hamil
The new microorganism Streptomyces granuloruber, NRRL 12389 and the fermentation process for preparing narasin by submerged aerobic fermentation of this organism.
312	Novel compound DC-38-V and process for production thereof	US175324	1980-08-04	US4340725A	1982-07-20	Fusao Tomita; Yuzura Matsuda; Kunikatsu Shirahata; Keiichi Takahashi; Hirofumi Nakano; Tomoyasu Sato; Shuji Okubo; Nobuo Nakamura
The antibacterial compound DC-38-V is produced by culturing a microorganism belonging to the genus Streptomyces.
313	Cleomycins and process for producing same	US167439	1980-07-09	US4326054A	1982-04-20	Hamao Umezawa; Tomohisa Takita; Akio Fujii; Yasuhiko Muraoka; Mamoru Kunishima
Novel antibiotics cleomycins represented by the formula ##STR1## wherein R is a terminal amino residue of the cleomycin. These compounds are useful as a chemotherapeutic agent for treating cancer and bacterial infections.
314	Antibiotic SF-1130-x.sub.3 3 substance and production and use thereof	US185592	1980-09-09	US4316894A	1982-02-23	Shoji Omoto; Jiro Itoh; Tomizo Niwa; Takashi Shomura; Tetsutaro Niizato; Shigeharu Inouye
A new antibiotic SF-1130-x.sub.3 substance is produced by cultivating a microorganism Streptomyces myxogenes SF-1130 (deposited under FERM-P. 676 and ATCC 31305) in a liquid culture medium under aerobic conditions, and this antibiotic may be isolated from the fermentation broth of said microorganism and is useful as an inhibitor to .alpha.-glucosidase and saccharase. Besides, this antibiotic, when orally given, is useful as a drug for suppressing an elevation in the level of blood sugar in living animals which have taken starch and/or sugars.
315	Peptide, process for preparation thereof and use thereof	US93523	1979-11-13	US4311640A	1982-01-19	Yoshio Kuroda; Eiko Iguchi; Masanobu Kohsaka; Hatsuo Aoki; Hiroshi Imanaka; Yoshihiko Kitaura; Osamu Nakaguchi; Keiji Hemmi; Matsuhiko Aratani; Hidekazu Takeno; Satoshi Okada; Hirokazu Tanaka; Masashi Hashimoto
The invention deals with novel peptides useful for the therapeutic treatment of infectious diseases caused by pathogenic microorganisms. Included is the peptide FR900156 having the structure: ##STR1## as well as the peptides of the structure ##STR2## wherein R.sup.1 is acyl;R.sub.b.sup.1 is hydrogen, methyl, isopropyl, hydroxymethyl, protected hydroxymethyl or benzyl;R.sup.2 is hydrogen, carboxy, protected carboxy, or a group of the formula: ##STR3## wherein R.sub.a.sup.2 is mono- or di-carboxy lower alkyl or ar(carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy,R.sub.b.sup.2 is hydrogen or lower alkyl;R.sup.p and R.sup.q are each hydrogen, carboxy, protected carboxy, with proviso that when one of R.sup.2 and R.sup.q is hydrogen, then the other is carboxy or protected carboxy;R.sup.r is hydrogen or amino protective group; m is an integer 1 to 3; and n is 1 provided that when R.sup.1 is hydrogen, t-butoxycarbonyl or N-acetylmuramyl, R.sub.b.sup.1 is methyl, m is an integer 2 and n is an integer 1, then R.sup.2 is hydrogen, protected carboxy or a group of the formula: ##STR4## wherein R.sub.a.sup.2 is mono- or di-carboxy lower alkyl having 1 and 3 to 6, carbon atoms, .alpha.-carboxyethyl, ar(carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy and R.sub.b.sup.2 is as defined above, or its pharmaceutically acceptable salt.
316	Demethyl maytansinoids	US153522	1980-05-27	US4307016A	1981-12-22	Mitsuko Asai; Kazuo Nakahama; Motowo Izawa
Novel demethylmaytansinoids representable by the formula: ##STR1## [wherein X is Cl or H; R.sub.1 is H or acyl group] are produced from maytansinoids by means of enzymic transformation. The demethylmaytansinoids are useful as antifungal, antiprotozoal or antitumor agents.
317	Anti-coccidial substance and its preparation	US948786	1978-10-05	US4293650A	1981-10-06	Jean Florent; Jean Lunel; Denise Mancy
37,454 RP of the formula: ##STR1## and its non-toxic salts with metals and nitrogen-containing bases possess anti-coccidial activity.
318	Process of producing antibiotic X-14766A by a streptomyces	US128992	1980-03-10	US4283493A	1981-08-11	Chao-Min Liu; John Westley
A compound of the formula ##STR1## and its pharmaceutically acceptable salts are disclosed. The compound exhibits antibacterial activity, antimalarial activity, has activity as a growth promotant for ruminants and as an agent in the treatment of swine dysentery. Also provided is a process to produce the novel compound.
319	Plasmid and process of isolating same	US17812	1979-03-05	US4273875A	1981-06-16	Jack J. Manis
A novel chemical compound, essentially pure plasmid pUC6, which is obtainable from a biologically pure culture of the microorganism Streptomyces espinosus biotype 23724a, NRRL 11439. The pUC6 plasmid is useful as a cloning vehicle in recombinant DNA work. For example, using DNA methodology, a desired gene, for example, the insulin gene, can be inserted into pUC6 and the resulting plasmid can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin.
320	Anthracycline derivatives and process for preparing the same	US75302	1979-09-12	US4267312A	1981-05-12	Toshikazu Oki; Akihiro Yoshimoto; Taiji Inui; Tomio Takeuchi; Hamao Umezawa
New anthracycline derivatives, 1-hydroxy-13-dihydrodaunomycin and N-formyl-1-hydroxy-13-dihydrodaunomycin are produced by microbial transformation of .epsilon.-pyrromycinone and .epsilon.-isorhodomycinone with daunomycin-producing streptomyces and their mutants. The derivatives herein are useful as cancer chemotherapeutic agents.

11 12 13 14 15 16 17 18 19 20

该功能需要专业版企业版VIP权限，您可以：